Stenger S, Donhauser N, Thüring H, Röllinghoff M, Bogdan C
Institute of Clinical Microbiology and Immunology, University of Erlangen, Germany.
J Exp Med. 1996 Apr 1;183(4):1501-14. doi: 10.1084/jem.183.4.1501.
Nitric oxide (NO) synthase (iNOS) is required for the resolution of acute cutaneous leishmaniasis in resistant C57BL/6 mice. As is the case in several other infections, the clinically cured host organism still harbors small amounts of live Leishmania major parasites. Here, we demonstrate lifelong expression of iNOS at the site of the original skin lesion and in the draining lymph node of long-term-infected C57BL/6 mice. iNOS activity in the lymph node was dependent on CD4+, but not on the CD8+ T cells. By double labeling techniques, iNOS and L. major were each found in macrophages (F4/80+, BM-8+, and/or MOMA-2+) and dendritic cells (NLDC-145+), but not in granulocytes or endothelial cells. In situ triple labeling of lymph node sections revealed that approximately 30-40% of the L. major foci were associated with iNOS-positive macrophages or dendritic cells. The majority of the L. major foci (60-70%), however, was located in areas that were negative for both iNOS and the macrophage and dendritic cell markers. In L. major-infected C57BL/6 mice, which had cured their cutaneous lesions, administration of L-N6-iminoethyl-lysine (L-NIL), a potent inhibitor of iNOS, led to a 10(4)-10(5)-fold increase of the parasite burden in the cutaneous and lymphoid tissue and caused clinical recrudescence of the disease. Persistent expression of iNOS and resumption of parasite replication after application of L-NIL was also observed in resistant C3H/HeN and CBA/J mice. We conclude that iNOS activity is crucial for the control of Leishmania persisting in immunocompetent hosts after resolution of the primary infection. Failure to maintain iNOS activity might be the mechanism underlying endogenous reactivation of latent infections with NO-sensitive microbes during phases of immunosuppression.
一氧化氮(NO)合酶(iNOS)对于抗性C57BL/6小鼠急性皮肤利什曼病的消退是必需的。与其他几种感染情况一样,临床治愈的宿主机体仍携带少量活的硕大利什曼原虫寄生虫。在此,我们证明了iNOS在长期感染的C57BL/6小鼠的原始皮肤损伤部位和引流淋巴结中终身表达。淋巴结中的iNOS活性依赖于CD4 + 细胞,但不依赖于CD8 + T细胞。通过双重标记技术,iNOS和硕大利什曼原虫均存在于巨噬细胞(F4/80 + 、BM-8 + 和/或MOMA-2 + )和树突状细胞(NLDC-145 + )中,但不存在于粒细胞或内皮细胞中。淋巴结切片的原位三重标记显示,约30 - 40%的硕大利什曼原虫病灶与iNOS阳性巨噬细胞或树突状细胞相关。然而,大多数硕大利什曼原虫病灶(60 - 70%)位于iNOS以及巨噬细胞和树突状细胞标志物均为阴性 的区域。在已治愈皮肤损伤的硕大利什曼原虫感染的C57BL/6小鼠中,给予iNOS的强效抑制剂L-N6-亚氨基乙基赖氨酸(L-NIL)导致皮肤和淋巴组织中的寄生虫负荷增加10^4 - 10^5倍,并引起疾病的临床复发。在抗性C3H/HeN和CBA/J小鼠中也观察到应用L-NIL后iNOS的持续表达和寄生虫复制的恢复。我们得出结论,iNOS活性对于控制初次感染消退后在免疫活性宿主体内持续存在的利什曼原虫至关重要。免疫抑制阶段未能维持iNOS活性可能是对NO敏感的微生物潜伏感染内源性再激活的潜在机制。